UIC registers Phase 1 trial of Pfizer's elranatamab in plasmablastic lymphoma
University of Illinois at Chicago has registered a feasibility study testing elranatamab as consolidation therapy for newly diagnosed plasmablastic lymphoma, with Pfizer as collaborator.
One item posted this week involving the company as a trial collaborator.
- A Phase 1 study titled "HEME-25 Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV in Consolidation After Definitive Therapy (The EPIC Study)"1 is sponsored by the University of Illinois at Chicago, with Pfizer listed as a collaborator1. The trial plans to enroll 17 participants1 who will receive elranatamab consolidation after achieving a complete or partial response from definitive frontline chemotherapy for plasmablastic lymphoma, with or without HIV1; the study has a start date of 2026-10-21 and an estimated primary completion date of 2029-12-011.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.